Hospital

Anthony Blaszczyk, PhD, explains the intricacy of CGT manufacturing demands, best practices, and how USP is supporting developers.

This decision builds upon the drug’s initial approval for adult patients and introduces a new therapeutic option for clinicians treating pediatric populations with rapid heart rate disturbances.

WHI data link radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

Beyond memantine's approved use in Alzheimer disease, emerging evidence highlights a possible role for it in select epilepsy cases.

The indication is to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic symptoms.

Emerging therapeutic options represent a new age for treatment of high-risk non–muscle invasive bladder cancer.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

Students should consider reaching out to their experiential education department to learn what opportunities may be available.

Real-world data show pharmacist-driven obesity care models may offer greater improvements in hemoglobin A1C and lipid parameters while supporting multidisciplinary, patient-centered care.

New evidence shows that human papillomavirus (HPV) 9-valent vaccine protection lasts up to 14 years. Learn why early vaccination and pharmacists can boost cancer prevention.

Cristian Tomasetti, PhD, explains how obesity enlarges organs, raising cancer risk, and how GLP-1 weight loss therapy may reverse this, guiding oncology pharmacists.

Early immune signals can program longer-lasting lung-resident T cells—a potential breakthrough for influenza and COVID-19 vaccine design.

LIV Process is a patented, water-based solution that allows hospitals and long-term care facilities to see live C difficile spores on surfaces in 2 minutes.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

Team-based hypertension care puts pharmacists and home blood pressure monitoring at the front line, boosting control rates and saving lives and costs.

Keytruda Qlex is a subcutaneous formulation of pembrolizumab that offers a faster, more convenient alternative to IV administration with comparable efficacy.

LTOT opioid therapy declines, but gabapentinoid coprescribing rises—impact on chronic pain management, safety, and prescriptions.

Therapy-related acute myeloid leukemia (tAML) increases as cancer therapy improves, spotlighting AML risk after chemotherapy or radiation and the need for vigilant oncology monitoring.

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.

Kyle Fischer, PharmD, explains navigating payer hurdles, supporting adherence, and improving coordination in ILD and PAH care.

A unified specialty pharmacy platform replaces fragmented tools, streamlines access, boosts reimbursement clarity, and supports advanced therapies.

Clinical pharmacists are uniquely positioned to deliver a continuation appropriateness measure that no existing quality framework produces.

This week's episode highlights new data on the newly approved oral GLP-1, orforglipron, the growing role of sports pharmacists, and FDA approval of a higher-dose regimen for spinal muscular atrophy.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Pacritinib bridges high-risk myelofibrosis to allogeneic stem cell transplantation, preserving blood counts, shrinking spleen and symptoms, and enabling 95% of patients to undergo transplantation.

Air pollution exposure, particularly fine particulate matter and ozone, may worsen cardiac outcomes in patients with breast cancer receiving cardiotoxic therapies.

Pharmacist Kyle Fischer, PharmD, APh, explains how antifibrotic therapy, drug interactions, and pharmacist–physician collaboration guide ILD care.